Angiotensin-converting enzyme inhibitors reduce mortality compared to angiotensin receptor blockers: Systematic review and meta-analysis

Lifestyle and risk factor management in people at high risk of cardiovascular disease. A report from the European Society of Cardiology European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) IV cross-sectional survey in 14 European regions

(2016) Kornelia Kotseva et al.   European Journal of Preventive Cardiology

ACE Inhibitor and ARB Utilization and Expenditures in the Medicaid Fee-For-Service Program from 1991 to 2008

(2016) Boyang Bian et al.   JOURNAL OF MANAGED CARE PHARMACY

Effects of ACEI/ARB in hypertensive patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled studies

(2014) Guang Hao et al.   BMC Cardiovascular Disorders

Systematic Review: Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II–Receptor Blockers for Ischemic Heart Disease

(2013) William L. Baker   ANNALS OF INTERNAL MEDICINE

2013 ESH/ESC Guidelines for the management of arterial hypertension

(2013)   EUROPEAN HEART JOURNAL

2013 ESC guidelines on the management of stable coronary artery disease

(2013)   EUROPEAN HEART JOURNAL

2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults

(2013) Paul A. James et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Bradykinin Antagonist Counteracts the Acute Effect of Both Angiotensin-Converting Enzyme Inhibition and of Angiotensin Receptor Blockade on the Lower Limit of Autoregulation of Cerebral Blood Flow

(2013) Sigurdur T Sigurdsson et al.   JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM

Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158 998 patients

(2012) L. C. van Vark et al.   EUROPEAN HEART JOURNAL

Prostaglandins and Inflammation

(2011) Emanuela Ricciotti et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study

(2011) E. Imai et al.   DIABETOLOGIA

The ROADMAP trial: olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes

(2011) Guido Grassi   EXPERT OPINION ON PHARMACOTHERAPY

Bradykinin-potentiating peptides: Beyond captopril

(2011) Antonio C.M. Camargo et al.   TOXICON

What is the proper workup of a patient with hypertension?

(2009) R. KATAKAM et al.   CLEVELAND CLINIC JOURNAL OF MEDICINE

Hypertension and the bradykinin system

(2009) Jagdish N. Sharma   CURRENT HYPERTENSION REPORTS

Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE)

(2009) H. Kasanuki et al.   EUROPEAN HEART JOURNAL

Prevention and regression of hypertension: role of renal microvascular protection

(2009) Hiroyuki Sasamura et al.   HYPERTENSION RESEARCH

Bradykinin protects against brain microvascular endothelial cell death induced by pathophysiological stimuli

(2009) Veronica Bovenzi et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2009) David Moher et al.   PLOS MEDICINE

Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events

(2008) Salim Yusuf et al.   NEW ENGLAND JOURNAL OF MEDICINE